Identifying responders to gabapentin for the treatment of alcohol use disorder: an exploratory machine learning approach.

Background Gabapentin, an anticonvulsant medication, has been proposed as a treatment for alcohol use disorder (AUD). A multisite study tested gabapentin enacarbil extended-release (GE-XR; 600 mg/twice a day), a prodrug formulation, combined with a computerized behavioral intervention, for AUD. In t...

Descripción completa

Detalles Bibliográficos
Publicado en:Alcohol & Alcoholism Vol. 60; no. 3; pp. 1 - 11
Autores principales: Ray, Lara A, Grodin, Erica N, Baskerville, Wave-Ananda, Donato, Suzanna, Cruz, Alondra, Montoya, Amanda K
Formato: research tables/charts Journal Article
Publicado: Oxford University Press / USA May2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=185488926&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 185488926
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        07350414
        FA3
      jtl: Alcohol & Alcoholism
      issn: 07350414
      maglogo: N
    pubinfo:
      dt: May2025
      vid: 60
      iid: 3
      pid: 622
      pub: Oxford University Press / USA
    artinfo:
      ui:
        185488926
        185488926
        185488926
        10.1093/alcalc/agaf010
        185488926
      ppf: 1
      ppct: 10
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Identifying responders to gabapentin for the treatment of alcohol use disorder: an exploratory machine learning approach.
      aug:
        au:
          Ray, Lara A
          Grodin, Erica N
          Baskerville, Wave-Ananda
          Donato, Suzanna
          Cruz, Alondra
          Montoya, Amanda K
        affil: Department of Psychology, University of California, Los Angeles, 1285 Franz Hall, Los Angeles, CA 90095, United States
      sug:
        subj:
          Alcoholism Drug Therapy
          Alcoholism Psychosocial Factors
          Gabapentin Administration and Dosage
          Gabapentin Therapeutic Use
          Anticonvulsants Therapeutic Use
          Machine Learning Methods
          Treatment Outcomes
          Human
          Funding Source
          Male
          Female
          Adult
          Middle Age
          Exploratory Research
          Secondary Analysis
          Multicenter Studies
          GABA Therapeutic Use
          GABA Analogs and Derivatives
          Acids, Acyclic
          Self-Efficacy
          Cognition
          Substance Withdrawal Syndrome
          Drug Development
          Decision Trees
          Iatrogenic Disease
          Placebos
          Motivation
          Descriptive Statistics
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Male
          Female
      ab: Background Gabapentin, an anticonvulsant medication, has been proposed as a treatment for alcohol use disorder (AUD). A multisite study tested gabapentin enacarbil extended-release (GE-XR; 600 mg/twice a day), a prodrug formulation, combined with a computerized behavioral intervention, for AUD. In this multisite trial, the gabapentin GE-XR group did not differ significantly from placebo on the primary outcome of percent of subjects with no heavy drinking days. Despite the null findings, there is considerable interest in using machine learning methods to identify responders to GE-XR. The present study applies interaction tree machine learning methods to identify positive and iatrogenic (i.e. individuals who responded better to placebo than to GE-XR) treatment responders in the trial. Methods Baseline characteristics taken from the multisite trial were examined as potential moderators of treatment response using qualitative interaction trees (QUINT; N  = 338; 223 M/115F). QUINT models are an exploratory decision tree approach that iteratively splits the data into leaves based on predictor variables to maximize a specific criterion. Results Analyses identified key factors that are associated with the efficacy (or iatrogenic effects) of GE-XR for AUD. Such factors are baseline drinking levels, motivation for change, confidence in their ability to reach drinking goals (i.e. self-efficacy), cognitive impulsivity, and baseline anxiety levels. Conclusion Baseline drinking levels and anxiety levels may be associated with the protracted withdrawal syndrome, previously implicated in the clinical response to gabapentin. However, these analyses underscore motivation for change and self-efficacy as predictors of clinical response to GE-XR, suggesting these established constructs should receive further attention in gabapentin research and clinical practice. Multiple studies using different machine learning methods are valuable as these novel analytic tools are applied to medication development for AUD.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N